nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—SIK1—dilated cardiomyopathy	0.383	0.585	CbGaD
Bosutinib—RPS6KB1—dilated cardiomyopathy	0.201	0.307	CbGaD
Bosutinib—EGFR—dilated cardiomyopathy	0.0703	0.107	CbGaD
Bosutinib—Gastric haemorrhage—Spironolactone—dilated cardiomyopathy	0.0132	0.195	CcSEcCtD
Bosutinib—BMPR2—pulmonary artery—dilated cardiomyopathy	0.00342	0.0343	CbGeAlD
Bosutinib—Drug eruption—Spironolactone—dilated cardiomyopathy	0.00269	0.0398	CcSEcCtD
Bosutinib—EPHA2—pulmonary artery—dilated cardiomyopathy	0.00243	0.0244	CbGeAlD
Bosutinib—Pancreatitis acute—Furosemide—dilated cardiomyopathy	0.00195	0.0288	CcSEcCtD
Bosutinib—MAP4K4—Testosterone Propionate—Spironolactone—dilated cardiomyopathy	0.0017	0.781	CbGdCrCtD
Bosutinib—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00162	0.024	CcSEcCtD
Bosutinib—Drug eruption—Furosemide—dilated cardiomyopathy	0.00146	0.0216	CcSEcCtD
Bosutinib—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.0013	0.0192	CcSEcCtD
Bosutinib—IKBKE—heart—dilated cardiomyopathy	0.00117	0.0118	CbGeAlD
Bosutinib—Vandetanib—EGFR—dilated cardiomyopathy	0.00113	0.513	CrCbGaD
Bosutinib—CLK3—cardiac ventricle—dilated cardiomyopathy	0.0011	0.011	CbGeAlD
Bosutinib—Gefitinib—EGFR—dilated cardiomyopathy	0.00107	0.487	CrCbGaD
Bosutinib—Gastritis—Spironolactone—dilated cardiomyopathy	0.00106	0.0157	CcSEcCtD
Bosutinib—EIF2AK1—cardiac ventricle—dilated cardiomyopathy	0.00106	0.0106	CbGeAlD
Bosutinib—CLK3—myocardium—dilated cardiomyopathy	0.00103	0.0103	CbGeAlD
Bosutinib—VRK2—cardiac ventricle—dilated cardiomyopathy	0.00103	0.0103	CbGeAlD
Bosutinib—TNIK—cardiac ventricle—dilated cardiomyopathy	0.00101	0.0101	CbGeAlD
Bosutinib—EIF2AK1—myocardium—dilated cardiomyopathy	0.000996	0.00998	CbGeAlD
Bosutinib—VRK2—myocardium—dilated cardiomyopathy	0.000965	0.00968	CbGeAlD
Bosutinib—TNIK—myocardium—dilated cardiomyopathy	0.000947	0.00949	CbGeAlD
Bosutinib—WEE1—cardiac ventricle—dilated cardiomyopathy	0.000946	0.00948	CbGeAlD
Bosutinib—DMPK—cardiac ventricle—dilated cardiomyopathy	0.000946	0.00948	CbGeAlD
Bosutinib—Renal failure—Spironolactone—dilated cardiomyopathy	0.000909	0.0134	CcSEcCtD
Bosutinib—WEE1—myocardium—dilated cardiomyopathy	0.00089	0.00892	CbGeAlD
Bosutinib—DMPK—myocardium—dilated cardiomyopathy	0.00089	0.00892	CbGeAlD
Bosutinib—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.000881	0.013	CcSEcCtD
Bosutinib—PLK2—cardiac ventricle—dilated cardiomyopathy	0.000879	0.00881	CbGeAlD
Bosutinib—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.000863	0.0128	CcSEcCtD
Bosutinib—PLK2—myocardium—dilated cardiomyopathy	0.000826	0.00828	CbGeAlD
Bosutinib—SIK3—myocardium—dilated cardiomyopathy	0.000821	0.00823	CbGeAlD
Bosutinib—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.000785	0.0116	CcSEcCtD
Bosutinib—TLK1—heart—dilated cardiomyopathy	0.000777	0.00779	CbGeAlD
Bosutinib—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.000762	0.0113	CcSEcCtD
Bosutinib—STK33—heart—dilated cardiomyopathy	0.000756	0.00758	CbGeAlD
Bosutinib—FER—myocardium—dilated cardiomyopathy	0.000747	0.00748	CbGeAlD
Bosutinib—DSTYK—heart—dilated cardiomyopathy	0.000719	0.00721	CbGeAlD
Bosutinib—CLK3—heart—dilated cardiomyopathy	0.000719	0.00721	CbGeAlD
Bosutinib—BMX—heart—dilated cardiomyopathy	0.000719	0.00721	CbGeAlD
Bosutinib—BMPR2—cardiac ventricle—dilated cardiomyopathy	0.000711	0.00713	CbGeAlD
Bosutinib—CASK—heart—dilated cardiomyopathy	0.000703	0.00704	CbGeAlD
Bosutinib—PHKG1—heart—dilated cardiomyopathy	0.000703	0.00704	CbGeAlD
Bosutinib—EIF2AK1—heart—dilated cardiomyopathy	0.000695	0.00697	CbGeAlD
Bosutinib—MAP4K4—cardiac ventricle—dilated cardiomyopathy	0.000685	0.00686	CbGeAlD
Bosutinib—BCR—cardiac ventricle—dilated cardiomyopathy	0.00068	0.00681	CbGeAlD
Bosutinib—FES—heart—dilated cardiomyopathy	0.000674	0.00675	CbGeAlD
Bosutinib—VRK2—heart—dilated cardiomyopathy	0.000674	0.00675	CbGeAlD
Bosutinib—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00067	0.00992	CcSEcCtD
Bosutinib—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.000663	0.00981	CcSEcCtD
Bosutinib—STK35—cardiac ventricle—dilated cardiomyopathy	0.000661	0.00663	CbGeAlD
Bosutinib—TNIK—heart—dilated cardiomyopathy	0.000661	0.00662	CbGeAlD
Bosutinib—CSK—cardiac ventricle—dilated cardiomyopathy	0.000657	0.00658	CbGeAlD
Bosutinib—CDK2—heart—dilated cardiomyopathy	0.000655	0.00656	CbGeAlD
Bosutinib—CSNK1A1—cardiac ventricle—dilated cardiomyopathy	0.000653	0.00654	CbGeAlD
Bosutinib—Malaise—Spironolactone—dilated cardiomyopathy	0.000651	0.00964	CcSEcCtD
Bosutinib—STK26—heart—dilated cardiomyopathy	0.000649	0.0065	CbGeAlD
Bosutinib—CLK1—cardiac ventricle—dilated cardiomyopathy	0.000649	0.0065	CbGeAlD
Bosutinib—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000647	0.00957	CcSEcCtD
Bosutinib—MAP4K4—myocardium—dilated cardiomyopathy	0.000644	0.00646	CbGeAlD
Bosutinib—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00064	0.00948	CcSEcCtD
Bosutinib—BCR—myocardium—dilated cardiomyopathy	0.000639	0.00641	CbGeAlD
Bosutinib—STK35—myocardium—dilated cardiomyopathy	0.000622	0.00623	CbGeAlD
Bosutinib—DMPK—heart—dilated cardiomyopathy	0.000621	0.00623	CbGeAlD
Bosutinib—WEE1—heart—dilated cardiomyopathy	0.000621	0.00623	CbGeAlD
Bosutinib—CSK—myocardium—dilated cardiomyopathy	0.000618	0.00619	CbGeAlD
Bosutinib—CLK3—cardiac atrium—dilated cardiomyopathy	0.000615	0.00616	CbGeAlD
Bosutinib—CSNK1A1—myocardium—dilated cardiomyopathy	0.000614	0.00615	CbGeAlD
Bosutinib—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000611	0.00905	CcSEcCtD
Bosutinib—HCK—myocardium—dilated cardiomyopathy	0.00061	0.00611	CbGeAlD
Bosutinib—CLK1—myocardium—dilated cardiomyopathy	0.00061	0.00611	CbGeAlD
Bosutinib—Discomfort—Spironolactone—dilated cardiomyopathy	0.000608	0.00899	CcSEcCtD
Bosutinib—Dehydration—Furosemide—dilated cardiomyopathy	0.000607	0.00898	CcSEcCtD
Bosutinib—CSNK1E—cardiac ventricle—dilated cardiomyopathy	0.000605	0.00606	CbGeAlD
Bosutinib—SIK1—cardiac ventricle—dilated cardiomyopathy	0.000595	0.00597	CbGeAlD
Bosutinib—EIF2AK1—cardiac atrium—dilated cardiomyopathy	0.000595	0.00596	CbGeAlD
Bosutinib—STK25—heart—dilated cardiomyopathy	0.000593	0.00595	CbGeAlD
Bosutinib—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00059	0.00872	CcSEcCtD
Bosutinib—EPHA3—heart—dilated cardiomyopathy	0.000589	0.0059	CbGeAlD
Bosutinib—MAP2K2—cardiac ventricle—dilated cardiomyopathy	0.000582	0.00584	CbGeAlD
Bosutinib—ULK3—cardiac ventricle—dilated cardiomyopathy	0.000582	0.00584	CbGeAlD
Bosutinib—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000577	0.00854	CcSEcCtD
Bosutinib—PLK2—heart—dilated cardiomyopathy	0.000577	0.00578	CbGeAlD
Bosutinib—VRK2—cardiac atrium—dilated cardiomyopathy	0.000576	0.00578	CbGeAlD
Bosutinib—SIK3—heart—dilated cardiomyopathy	0.000573	0.00574	CbGeAlD
Bosutinib—MAP3K7—cardiac ventricle—dilated cardiomyopathy	0.000573	0.00574	CbGeAlD
Bosutinib—TBK1—cardiac ventricle—dilated cardiomyopathy	0.000566	0.00567	CbGeAlD
Bosutinib—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.00056	0.00829	CcSEcCtD
Bosutinib—SIK1—myocardium—dilated cardiomyopathy	0.00056	0.00561	CbGeAlD
Bosutinib—IRAK1—cardiac ventricle—dilated cardiomyopathy	0.000555	0.00556	CbGeAlD
Bosutinib—EPHA4—myocardium—dilated cardiomyopathy	0.000554	0.00556	CbGeAlD
Bosutinib—STK4—heart—dilated cardiomyopathy	0.000552	0.00553	CbGeAlD
Bosutinib—ULK3—myocardium—dilated cardiomyopathy	0.000548	0.00549	CbGeAlD
Bosutinib—MAP2K2—myocardium—dilated cardiomyopathy	0.000548	0.00549	CbGeAlD
Bosutinib—CAMK1D—heart—dilated cardiomyopathy	0.000545	0.00546	CbGeAlD
Bosutinib—RPS6KB1—cardiac ventricle—dilated cardiomyopathy	0.000545	0.00546	CbGeAlD
Bosutinib—AXL—cardiac ventricle—dilated cardiomyopathy	0.000539	0.0054	CbGeAlD
Bosutinib—STK24—heart—dilated cardiomyopathy	0.000539	0.0054	CbGeAlD
Bosutinib—MAP3K7—myocardium—dilated cardiomyopathy	0.000539	0.0054	CbGeAlD
Bosutinib—PTK2—myocardium—dilated cardiomyopathy	0.000533	0.00534	CbGeAlD
Bosutinib—TBK1—myocardium—dilated cardiomyopathy	0.000533	0.00534	CbGeAlD
Bosutinib—DMPK—cardiac atrium—dilated cardiomyopathy	0.000531	0.00533	CbGeAlD
Bosutinib—WEE1—cardiac atrium—dilated cardiomyopathy	0.000531	0.00533	CbGeAlD
Bosutinib—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00053	0.00785	CcSEcCtD
Bosutinib—IRAK1—myocardium—dilated cardiomyopathy	0.000522	0.00523	CbGeAlD
Bosutinib—FER—heart—dilated cardiomyopathy	0.000521	0.00522	CbGeAlD
Bosutinib—SLK—cardiac ventricle—dilated cardiomyopathy	0.000519	0.0052	CbGeAlD
Bosutinib—EPHB4—cardiac ventricle—dilated cardiomyopathy	0.000515	0.00516	CbGeAlD
Bosutinib—Renal impairment—Lisinopril—dilated cardiomyopathy	0.000515	0.00761	CcSEcCtD
Bosutinib—RPS6KB1—myocardium—dilated cardiomyopathy	0.000512	0.00513	CbGeAlD
Bosutinib—MAP4K1—heart—dilated cardiomyopathy	0.000511	0.00512	CbGeAlD
Bosutinib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000509	0.00753	CcSEcCtD
Bosutinib—STK25—cardiac atrium—dilated cardiomyopathy	0.000507	0.00509	CbGeAlD
Bosutinib—AXL—myocardium—dilated cardiomyopathy	0.000507	0.00508	CbGeAlD
Bosutinib—FYN—cardiac ventricle—dilated cardiomyopathy	0.000505	0.00506	CbGeAlD
Bosutinib—TNK2—heart—dilated cardiomyopathy	0.000501	0.00502	CbGeAlD
Bosutinib—Renal failure—Furosemide—dilated cardiomyopathy	0.000494	0.00732	CcSEcCtD
Bosutinib—MAP4K2—heart—dilated cardiomyopathy	0.000494	0.00495	CbGeAlD
Bosutinib—PLK2—cardiac atrium—dilated cardiomyopathy	0.000493	0.00494	CbGeAlD
Bosutinib—MAP3K3—cardiac ventricle—dilated cardiomyopathy	0.000493	0.00494	CbGeAlD
Bosutinib—SIK3—cardiac atrium—dilated cardiomyopathy	0.00049	0.00491	CbGeAlD
Bosutinib—SLK—myocardium—dilated cardiomyopathy	0.000488	0.00489	CbGeAlD
Bosutinib—STK3—heart—dilated cardiomyopathy	0.000487	0.00488	CbGeAlD
Bosutinib—ERBB4—heart—dilated cardiomyopathy	0.000487	0.00488	CbGeAlD
Bosutinib—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000486	0.00719	CcSEcCtD
Bosutinib—EPHB4—myocardium—dilated cardiomyopathy	0.000485	0.00486	CbGeAlD
Bosutinib—ROCK1—heart—dilated cardiomyopathy	0.000481	0.00482	CbGeAlD
Bosutinib—CHEK2—Testosterone Propionate—Spironolactone—dilated cardiomyopathy	0.000478	0.219	CbGdCrCtD
Bosutinib—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000476	0.00704	CcSEcCtD
Bosutinib—FYN—myocardium—dilated cardiomyopathy	0.000475	0.00476	CbGeAlD
Bosutinib—Face oedema—Lisinopril—dilated cardiomyopathy	0.000473	0.007	CcSEcCtD
Bosutinib—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.000469	0.00694	CcSEcCtD
Bosutinib—Urticaria—Spironolactone—dilated cardiomyopathy	0.000468	0.00693	CcSEcCtD
Bosutinib—BMPR2—heart—dilated cardiomyopathy	0.000467	0.00468	CbGeAlD
Bosutinib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000466	0.0069	CcSEcCtD
Bosutinib—CAMK1D—cardiac atrium—dilated cardiomyopathy	0.000466	0.00467	CbGeAlD
Bosutinib—MAP3K3—myocardium—dilated cardiomyopathy	0.000464	0.00465	CbGeAlD
Bosutinib—STK36—heart—dilated cardiomyopathy	0.000463	0.00464	CbGeAlD
Bosutinib—EPHB3—heart—dilated cardiomyopathy	0.000463	0.00464	CbGeAlD
Bosutinib—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000459	0.00679	CcSEcCtD
Bosutinib—MERTK—heart—dilated cardiomyopathy	0.000458	0.00459	CbGeAlD
Bosutinib—Dehydration—Lisinopril—dilated cardiomyopathy	0.000455	0.00674	CcSEcCtD
Bosutinib—YES1—cardiac ventricle—dilated cardiomyopathy	0.000455	0.00456	CbGeAlD
Bosutinib—MAP4K4—heart—dilated cardiomyopathy	0.00045	0.00451	CbGeAlD
Bosutinib—TAOK3—cardiac ventricle—dilated cardiomyopathy	0.00045	0.00451	CbGeAlD
Bosutinib—BCR—heart—dilated cardiomyopathy	0.000446	0.00447	CbGeAlD
Bosutinib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000446	0.0066	CcSEcCtD
Bosutinib—FER—cardiac atrium—dilated cardiomyopathy	0.000446	0.00447	CbGeAlD
Bosutinib—MAP3K12—heart—dilated cardiomyopathy	0.000443	0.00444	CbGeAlD
Bosutinib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000443	0.00655	CcSEcCtD
Bosutinib—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000438	0.00648	CcSEcCtD
Bosutinib—MAP2K1—heart—dilated cardiomyopathy	0.000434	0.00435	CbGeAlD
Bosutinib—STK35—heart—dilated cardiomyopathy	0.000434	0.00435	CbGeAlD
Bosutinib—Gastritis—Lisinopril—dilated cardiomyopathy	0.000433	0.00641	CcSEcCtD
Bosutinib—CSK—heart—dilated cardiomyopathy	0.000431	0.00432	CbGeAlD
Bosutinib—CSNK1A1—heart—dilated cardiomyopathy	0.000429	0.0043	CbGeAlD
Bosutinib—YES1—myocardium—dilated cardiomyopathy	0.000428	0.00429	CbGeAlD
Bosutinib—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000427	0.00632	CcSEcCtD
Bosutinib—HCK—heart—dilated cardiomyopathy	0.000426	0.00427	CbGeAlD
Bosutinib—CLK1—heart—dilated cardiomyopathy	0.000426	0.00427	CbGeAlD
Bosutinib—Influenza—Lisinopril—dilated cardiomyopathy	0.000423	0.00626	CcSEcCtD
Bosutinib—ABL2—heart—dilated cardiomyopathy	0.000423	0.00424	CbGeAlD
Bosutinib—TAOK3—myocardium—dilated cardiomyopathy	0.000423	0.00424	CbGeAlD
Bosutinib—Tinnitus—Furosemide—dilated cardiomyopathy	0.000421	0.00623	CcSEcCtD
Bosutinib—BMP2K—heart—dilated cardiomyopathy	0.000418	0.00419	CbGeAlD
Bosutinib—CAMK2G—heart—dilated cardiomyopathy	0.000418	0.00419	CbGeAlD
Bosutinib—Pruritus—Spironolactone—dilated cardiomyopathy	0.000417	0.00617	CcSEcCtD
Bosutinib—ERBB4—cardiac atrium—dilated cardiomyopathy	0.000417	0.00418	CbGeAlD
Bosutinib—LRRK2—heart—dilated cardiomyopathy	0.000414	0.00415	CbGeAlD
Bosutinib—EGFR—heart—dilated cardiomyopathy	0.000413	0.00414	CbGeAlD
Bosutinib—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000408	0.00603	CcSEcCtD
Bosutinib—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000407	0.00602	CcSEcCtD
Bosutinib—PTK2B—heart—dilated cardiomyopathy	0.000404	0.00405	CbGeAlD
Bosutinib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000403	0.00597	CcSEcCtD
Bosutinib—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000402	0.00595	CcSEcCtD
Bosutinib—BMPR2—cardiac atrium—dilated cardiomyopathy	0.000399	0.004	CbGeAlD
Bosutinib—CSNK1E—heart—dilated cardiomyopathy	0.000397	0.00398	CbGeAlD
Bosutinib—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000396	0.00586	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000393	0.00582	CcSEcCtD
Bosutinib—Malnutrition—Furosemide—dilated cardiomyopathy	0.000393	0.00582	CcSEcCtD
Bosutinib—SIK1—heart—dilated cardiomyopathy	0.000391	0.00392	CbGeAlD
Bosutinib—IRAK4—heart—dilated cardiomyopathy	0.000391	0.00392	CbGeAlD
Bosutinib—Dizziness—Spironolactone—dilated cardiomyopathy	0.00039	0.00577	CcSEcCtD
Bosutinib—EPHA4—heart—dilated cardiomyopathy	0.000387	0.00388	CbGeAlD
Bosutinib—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000385	0.0057	CcSEcCtD
Bosutinib—MAP4K4—cardiac atrium—dilated cardiomyopathy	0.000385	0.00385	CbGeAlD
Bosutinib—ERBB3—heart—dilated cardiomyopathy	0.000383	0.00384	CbGeAlD
Bosutinib—ULK3—heart—dilated cardiomyopathy	0.000382	0.00383	CbGeAlD
Bosutinib—MAP2K2—heart—dilated cardiomyopathy	0.000382	0.00383	CbGeAlD
Bosutinib—BCR—cardiac atrium—dilated cardiomyopathy	0.000382	0.00383	CbGeAlD
Bosutinib—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00038	0.00562	CcSEcCtD
Bosutinib—MAP3K2—heart—dilated cardiomyopathy	0.00038	0.0038	CbGeAlD
Bosutinib—MAP2K5—myocardium—dilated cardiomyopathy	0.000379	0.0038	CbGeAlD
Bosutinib—MAP3K12—cardiac atrium—dilated cardiomyopathy	0.000379	0.0038	CbGeAlD
Bosutinib—MAP3K7—heart—dilated cardiomyopathy	0.000376	0.00377	CbGeAlD
Bosutinib—Vomiting—Spironolactone—dilated cardiomyopathy	0.000375	0.00555	CcSEcCtD
Bosutinib—Rash—Spironolactone—dilated cardiomyopathy	0.000372	0.0055	CcSEcCtD
Bosutinib—PTK2—heart—dilated cardiomyopathy	0.000372	0.00373	CbGeAlD
Bosutinib—TBK1—heart—dilated cardiomyopathy	0.000372	0.00373	CbGeAlD
Bosutinib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000371	0.0055	CcSEcCtD
Bosutinib—STK35—cardiac atrium—dilated cardiomyopathy	0.000371	0.00372	CbGeAlD
Bosutinib—Renal failure—Lisinopril—dilated cardiomyopathy	0.000371	0.00549	CcSEcCtD
Bosutinib—Headache—Spironolactone—dilated cardiomyopathy	0.000369	0.00547	CcSEcCtD
Bosutinib—CSK—cardiac atrium—dilated cardiomyopathy	0.000369	0.0037	CbGeAlD
Bosutinib—CSNK1A1—cardiac atrium—dilated cardiomyopathy	0.000367	0.00367	CbGeAlD
Bosutinib—IRAK1—heart—dilated cardiomyopathy	0.000364	0.00365	CbGeAlD
Bosutinib—CLK1—cardiac atrium—dilated cardiomyopathy	0.000364	0.00365	CbGeAlD
Bosutinib—Anaemia—Furosemide—dilated cardiomyopathy	0.000363	0.00538	CcSEcCtD
Bosutinib—RPS6KB1—heart—dilated cardiomyopathy	0.000358	0.00358	CbGeAlD
Bosutinib—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000357	0.00528	CcSEcCtD
Bosutinib—FGR—heart—dilated cardiomyopathy	0.000355	0.00356	CbGeAlD
Bosutinib—LCK—heart—dilated cardiomyopathy	0.000355	0.00356	CbGeAlD
Bosutinib—AXL—heart—dilated cardiomyopathy	0.000354	0.00355	CbGeAlD
Bosutinib—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000352	0.00521	CcSEcCtD
Bosutinib—Leukopenia—Furosemide—dilated cardiomyopathy	0.000352	0.00521	CcSEcCtD
Bosutinib—Nausea—Spironolactone—dilated cardiomyopathy	0.00035	0.00518	CcSEcCtD
Bosutinib—PDGFRB—cardiac ventricle—dilated cardiomyopathy	0.000349	0.0035	CbGeAlD
Bosutinib—SLK—heart—dilated cardiomyopathy	0.000341	0.00341	CbGeAlD
Bosutinib—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000339	0.00501	CcSEcCtD
Bosutinib—EPHB4—heart—dilated cardiomyopathy	0.000338	0.00339	CbGeAlD
Bosutinib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000335	0.00495	CcSEcCtD
Bosutinib—SIK1—cardiac atrium—dilated cardiomyopathy	0.000334	0.00335	CbGeAlD
Bosutinib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000334	0.00494	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000332	0.00492	CcSEcCtD
Bosutinib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000332	0.00491	CcSEcCtD
Bosutinib—EPHA2—heart—dilated cardiomyopathy	0.000332	0.00333	CbGeAlD
Bosutinib—FYN—heart—dilated cardiomyopathy	0.000331	0.00332	CbGeAlD
Bosutinib—EPHA4—cardiac atrium—dilated cardiomyopathy	0.000331	0.00332	CbGeAlD
Bosutinib—PDGFRB—myocardium—dilated cardiomyopathy	0.000328	0.00329	CbGeAlD
Bosutinib—MAP2K2—cardiac atrium—dilated cardiomyopathy	0.000327	0.00328	CbGeAlD
Bosutinib—ULK3—cardiac atrium—dilated cardiomyopathy	0.000327	0.00328	CbGeAlD
Bosutinib—MAP3K3—heart—dilated cardiomyopathy	0.000324	0.00324	CbGeAlD
Bosutinib—MAP4K5—heart—dilated cardiomyopathy	0.000324	0.00324	CbGeAlD
Bosutinib—MAP3K7—cardiac atrium—dilated cardiomyopathy	0.000322	0.00322	CbGeAlD
Bosutinib—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000321	0.00475	CcSEcCtD
Bosutinib—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00032	0.00474	CcSEcCtD
Bosutinib—TBK1—cardiac atrium—dilated cardiomyopathy	0.000318	0.00319	CbGeAlD
Bosutinib—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000316	0.00467	CcSEcCtD
Bosutinib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000315	0.00465	CcSEcCtD
Bosutinib—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000314	0.00465	CcSEcCtD
Bosutinib—Skin disorder—Furosemide—dilated cardiomyopathy	0.000312	0.00461	CcSEcCtD
Bosutinib—ABL1—cardiac ventricle—dilated cardiomyopathy	0.000311	0.00312	CbGeAlD
Bosutinib—RPS6KB1—cardiac atrium—dilated cardiomyopathy	0.000306	0.00307	CbGeAlD
Bosutinib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000305	0.00452	CcSEcCtD
Bosutinib—AXL—cardiac atrium—dilated cardiomyopathy	0.000303	0.00303	CbGeAlD
Bosutinib—YES1—heart—dilated cardiomyopathy	0.000299	0.003	CbGeAlD
Bosutinib—STK10—heart—dilated cardiomyopathy	0.000296	0.00297	CbGeAlD
Bosutinib—TAOK3—heart—dilated cardiomyopathy	0.000295	0.00296	CbGeAlD
Bosutinib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000295	0.00436	CcSEcCtD
Bosutinib—ABL1—myocardium—dilated cardiomyopathy	0.000292	0.00293	CbGeAlD
Bosutinib—SLK—cardiac atrium—dilated cardiomyopathy	0.000291	0.00292	CbGeAlD
Bosutinib—EPHB4—cardiac atrium—dilated cardiomyopathy	0.000289	0.0029	CbGeAlD
Bosutinib—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000289	0.00427	CcSEcCtD
Bosutinib—SRC—heart—dilated cardiomyopathy	0.000288	0.00288	CbGeAlD
Bosutinib—Back pain—Lisinopril—dilated cardiomyopathy	0.000285	0.00422	CcSEcCtD
Bosutinib—EPHA2—cardiac atrium—dilated cardiomyopathy	0.000284	0.00284	CbGeAlD
Bosutinib—FYN—cardiac atrium—dilated cardiomyopathy	0.000283	0.00284	CbGeAlD
Bosutinib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000279	0.00413	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000277	0.0041	CcSEcCtD
Bosutinib—MAP4K5—cardiac atrium—dilated cardiomyopathy	0.000277	0.00278	CbGeAlD
Bosutinib—MAP3K3—cardiac atrium—dilated cardiomyopathy	0.000277	0.00278	CbGeAlD
Bosutinib—Fatigue—Furosemide—dilated cardiomyopathy	0.000277	0.00409	CcSEcCtD
Bosutinib—Pain—Furosemide—dilated cardiomyopathy	0.000274	0.00406	CcSEcCtD
Bosutinib—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000274	0.00405	CcSEcCtD
Bosutinib—Anaemia—Lisinopril—dilated cardiomyopathy	0.000273	0.00403	CcSEcCtD
Bosutinib—Malaise—Lisinopril—dilated cardiomyopathy	0.000266	0.00393	CcSEcCtD
Bosutinib—MAP2K5—heart—dilated cardiomyopathy	0.000265	0.00265	CbGeAlD
Bosutinib—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000264	0.00391	CcSEcCtD
Bosutinib—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000264	0.00391	CcSEcCtD
Bosutinib—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000262	0.00388	CcSEcCtD
Bosutinib—CSF1R—heart—dilated cardiomyopathy	0.000258	0.00259	CbGeAlD
Bosutinib—Cough—Lisinopril—dilated cardiomyopathy	0.000257	0.00381	CcSEcCtD
Bosutinib—YES1—cardiac atrium—dilated cardiomyopathy	0.000256	0.00256	CbGeAlD
Bosutinib—Urticaria—Furosemide—dilated cardiomyopathy	0.000255	0.00377	CcSEcCtD
Bosutinib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000254	0.00375	CcSEcCtD
Bosutinib—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000254	0.00375	CcSEcCtD
Bosutinib—TAOK3—cardiac atrium—dilated cardiomyopathy	0.000252	0.00253	CbGeAlD
Bosutinib—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000251	0.00371	CcSEcCtD
Bosutinib—Chest pain—Lisinopril—dilated cardiomyopathy	0.000251	0.00371	CcSEcCtD
Bosutinib—Myalgia—Lisinopril—dilated cardiomyopathy	0.000251	0.00371	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000249	0.00369	CcSEcCtD
Bosutinib—Discomfort—Lisinopril—dilated cardiomyopathy	0.000248	0.00367	CcSEcCtD
Bosutinib—SRC—cardiac atrium—dilated cardiomyopathy	0.000246	0.00247	CbGeAlD
Bosutinib—Oedema—Lisinopril—dilated cardiomyopathy	0.000241	0.00356	CcSEcCtD
Bosutinib—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000241	0.00356	CcSEcCtD
Bosutinib—Infection—Lisinopril—dilated cardiomyopathy	0.000239	0.00354	CcSEcCtD
Bosutinib—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000236	0.00349	CcSEcCtD
Bosutinib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000234	0.00346	CcSEcCtD
Bosutinib—Asthenia—Furosemide—dilated cardiomyopathy	0.00023	0.00341	CcSEcCtD
Bosutinib—PDGFRB—heart—dilated cardiomyopathy	0.000229	0.0023	CbGeAlD
Bosutinib—Pruritus—Furosemide—dilated cardiomyopathy	0.000227	0.00336	CcSEcCtD
Bosutinib—MAP2K5—cardiac atrium—dilated cardiomyopathy	0.000226	0.00227	CbGeAlD
Bosutinib—CSF1R—cardiac atrium—dilated cardiomyopathy	0.000221	0.00221	CbGeAlD
Bosutinib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000219	0.00325	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000219	0.00324	CcSEcCtD
Bosutinib—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000215	0.00317	CcSEcCtD
Bosutinib—Dizziness—Furosemide—dilated cardiomyopathy	0.000212	0.00314	CcSEcCtD
Bosutinib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000209	0.0031	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000208	0.00307	CcSEcCtD
Bosutinib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000208	0.00307	CcSEcCtD
Bosutinib—Pain—Lisinopril—dilated cardiomyopathy	0.000206	0.00305	CcSEcCtD
Bosutinib—ABL1—heart—dilated cardiomyopathy	0.000204	0.00205	CbGeAlD
Bosutinib—Vomiting—Furosemide—dilated cardiomyopathy	0.000204	0.00302	CcSEcCtD
Bosutinib—Rash—Furosemide—dilated cardiomyopathy	0.000202	0.00299	CcSEcCtD
Bosutinib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000202	0.00299	CcSEcCtD
Bosutinib—Headache—Furosemide—dilated cardiomyopathy	0.000201	0.00297	CcSEcCtD
Bosutinib—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000198	0.00293	CcSEcCtD
Bosutinib—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000197	0.00291	CcSEcCtD
Bosutinib—PDGFRB—cardiac atrium—dilated cardiomyopathy	0.000196	0.00196	CbGeAlD
Bosutinib—Urticaria—Lisinopril—dilated cardiomyopathy	0.000191	0.00283	CcSEcCtD
Bosutinib—Nausea—Furosemide—dilated cardiomyopathy	0.000191	0.00282	CcSEcCtD
Bosutinib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00019	0.00282	CcSEcCtD
Bosutinib—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00019	0.00282	CcSEcCtD
Bosutinib—ABL1—cardiac atrium—dilated cardiomyopathy	0.000175	0.00175	CbGeAlD
Bosutinib—Asthenia—Lisinopril—dilated cardiomyopathy	0.000173	0.00256	CcSEcCtD
Bosutinib—Pruritus—Lisinopril—dilated cardiomyopathy	0.00017	0.00252	CcSEcCtD
Bosutinib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000165	0.00244	CcSEcCtD
Bosutinib—Dizziness—Lisinopril—dilated cardiomyopathy	0.000159	0.00235	CcSEcCtD
Bosutinib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000153	0.00226	CcSEcCtD
Bosutinib—Rash—Lisinopril—dilated cardiomyopathy	0.000152	0.00225	CcSEcCtD
Bosutinib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000152	0.00224	CcSEcCtD
Bosutinib—Headache—Lisinopril—dilated cardiomyopathy	0.000151	0.00223	CcSEcCtD
Bosutinib—Nausea—Lisinopril—dilated cardiomyopathy	0.000143	0.00212	CcSEcCtD
Bosutinib—ABCB1—heart—dilated cardiomyopathy	6.35e-05	0.000636	CbGeAlD
Bosutinib—ROCK1—Signaling Pathways—AGT—dilated cardiomyopathy	3.03e-06	1.75e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—RAF1—dilated cardiomyopathy	3.02e-06	1.75e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.02e-06	1.74e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.01e-06	1.74e-05	CbGpPWpGaD
Bosutinib—CSK—Disease—EGFR—dilated cardiomyopathy	3e-06	1.73e-05	CbGpPWpGaD
Bosutinib—YES1—Adaptive Immune System—EGFR—dilated cardiomyopathy	3e-06	1.73e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—EGFR—dilated cardiomyopathy	2.99e-06	1.72e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—RAC1—dilated cardiomyopathy	2.99e-06	1.72e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.98e-06	1.72e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—RAC1—dilated cardiomyopathy	2.97e-06	1.72e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling by NGF—EGFR—dilated cardiomyopathy	2.97e-06	1.71e-05	CbGpPWpGaD
Bosutinib—IRAK1—Innate Immune System—EGFR—dilated cardiomyopathy	2.97e-06	1.71e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—RAC1—dilated cardiomyopathy	2.95e-06	1.7e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—RAC1—dilated cardiomyopathy	2.94e-06	1.7e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—RAC1—dilated cardiomyopathy	2.92e-06	1.69e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AGT—dilated cardiomyopathy	2.92e-06	1.69e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AGT—dilated cardiomyopathy	2.92e-06	1.69e-05	CbGpPWpGaD
Bosutinib—TBK1—Immune System—EGFR—dilated cardiomyopathy	2.92e-06	1.69e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.91e-06	1.68e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.9e-06	1.67e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.9e-06	1.67e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—RAF1—dilated cardiomyopathy	2.89e-06	1.67e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—RAC1—dilated cardiomyopathy	2.89e-06	1.67e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	2.88e-06	1.66e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.87e-06	1.65e-05	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—EGFR—dilated cardiomyopathy	2.87e-06	1.65e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AGT—dilated cardiomyopathy	2.82e-06	1.63e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—RAC1—dilated cardiomyopathy	2.82e-06	1.63e-05	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—EGFR—dilated cardiomyopathy	2.8e-06	1.62e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.79e-06	1.61e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.79e-06	1.61e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—RAF1—dilated cardiomyopathy	2.79e-06	1.61e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—RAF1—dilated cardiomyopathy	2.79e-06	1.61e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—EGFR—dilated cardiomyopathy	2.79e-06	1.61e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—RAF1—dilated cardiomyopathy	2.79e-06	1.61e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.79e-06	1.61e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.78e-06	1.6e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—RAF1—dilated cardiomyopathy	2.78e-06	1.6e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—EGFR—dilated cardiomyopathy	2.76e-06	1.6e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.74e-06	1.58e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—RAF1—dilated cardiomyopathy	2.74e-06	1.58e-05	CbGpPWpGaD
Bosutinib—BTK—Immune System—EGFR—dilated cardiomyopathy	2.72e-06	1.57e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.72e-06	1.57e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—RAC1—dilated cardiomyopathy	2.71e-06	1.57e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	2.71e-06	1.56e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—RAC1—dilated cardiomyopathy	2.7e-06	1.56e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—ITGB1—dilated cardiomyopathy	2.7e-06	1.56e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.7e-06	1.56e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD36—dilated cardiomyopathy	2.69e-06	1.56e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—RAF1—dilated cardiomyopathy	2.69e-06	1.55e-05	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—EGFR—dilated cardiomyopathy	2.68e-06	1.55e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.68e-06	1.55e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.68e-06	1.55e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—RAF1—dilated cardiomyopathy	2.68e-06	1.54e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AGT—dilated cardiomyopathy	2.66e-06	1.53e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—RAF1—dilated cardiomyopathy	2.66e-06	1.53e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—EGFR—dilated cardiomyopathy	2.64e-06	1.52e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—TNF—dilated cardiomyopathy	2.63e-06	1.52e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—EGFR—dilated cardiomyopathy	2.63e-06	1.52e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—RAC1—dilated cardiomyopathy	2.63e-06	1.52e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.62e-06	1.51e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—EGFR—dilated cardiomyopathy	2.61e-06	1.51e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.61e-06	1.51e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.6e-06	1.5e-05	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—EGFR—dilated cardiomyopathy	2.6e-06	1.5e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—EGFR—dilated cardiomyopathy	2.6e-06	1.5e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.6e-06	1.5e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD36—dilated cardiomyopathy	2.6e-06	1.5e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.59e-06	1.49e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—EGFR—dilated cardiomyopathy	2.58e-06	1.49e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.58e-06	1.49e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.57e-06	1.48e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—RAF1—dilated cardiomyopathy	2.57e-06	1.48e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.56e-06	1.48e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.54e-06	1.47e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—RAC1—dilated cardiomyopathy	2.54e-06	1.47e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—RAF1—dilated cardiomyopathy	2.52e-06	1.45e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.52e-06	1.45e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—TNF—dilated cardiomyopathy	2.51e-06	1.45e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—EGFR—dilated cardiomyopathy	2.51e-06	1.45e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AGT—dilated cardiomyopathy	2.51e-06	1.45e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—TNF—dilated cardiomyopathy	2.5e-06	1.44e-05	CbGpPWpGaD
Bosutinib—HCK—Immune System—EGFR—dilated cardiomyopathy	2.5e-06	1.44e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.49e-06	1.44e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—TNF—dilated cardiomyopathy	2.47e-06	1.43e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AGT—dilated cardiomyopathy	2.47e-06	1.43e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.47e-06	1.43e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.47e-06	1.43e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—RAF1—dilated cardiomyopathy	2.47e-06	1.42e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—TNF—dilated cardiomyopathy	2.46e-06	1.42e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.46e-06	1.42e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	2.45e-06	1.41e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.45e-06	1.41e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—RAC1—dilated cardiomyopathy	2.45e-06	1.41e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.44e-06	1.41e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—EGFR—dilated cardiomyopathy	2.44e-06	1.41e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.44e-06	1.41e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	2.42e-06	1.4e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—EGFR—dilated cardiomyopathy	2.38e-06	1.37e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—RAF1—dilated cardiomyopathy	2.37e-06	1.37e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—RAF1—dilated cardiomyopathy	2.37e-06	1.37e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—EGFR—dilated cardiomyopathy	2.35e-06	1.36e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AGT—dilated cardiomyopathy	2.35e-06	1.35e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—RAC1—dilated cardiomyopathy	2.34e-06	1.35e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—EGFR—dilated cardiomyopathy	2.33e-06	1.35e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—EGFR—dilated cardiomyopathy	2.32e-06	1.34e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—EGFR—dilated cardiomyopathy	2.32e-06	1.34e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—RAC1—dilated cardiomyopathy	2.31e-06	1.34e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	2.31e-06	1.33e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—EGFR—dilated cardiomyopathy	2.31e-06	1.33e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.3e-06	1.33e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD36—dilated cardiomyopathy	2.3e-06	1.33e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—EGFR—dilated cardiomyopathy	2.29e-06	1.33e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.29e-06	1.32e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—EGFR—dilated cardiomyopathy	2.28e-06	1.32e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.27e-06	1.31e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—EGFR—dilated cardiomyopathy	2.26e-06	1.31e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—RAC1—dilated cardiomyopathy	2.26e-06	1.3e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—EGFR—dilated cardiomyopathy	2.26e-06	1.3e-05	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.24e-06	1.29e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.24e-06	1.29e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.23e-06	1.29e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.23e-06	1.29e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—EGFR—dilated cardiomyopathy	2.22e-06	1.28e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—RAF1—dilated cardiomyopathy	2.22e-06	1.28e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AGT—dilated cardiomyopathy	2.21e-06	1.28e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.2e-06	1.27e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—RAF1—dilated cardiomyopathy	2.19e-06	1.26e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.18e-06	1.26e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—EGFR—dilated cardiomyopathy	2.18e-06	1.26e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.18e-06	1.26e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—EGFR—dilated cardiomyopathy	2.17e-06	1.25e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—RAC1—dilated cardiomyopathy	2.17e-06	1.25e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.15e-06	1.24e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—TNF—dilated cardiomyopathy	2.14e-06	1.23e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.14e-06	1.23e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.12e-06	1.23e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.12e-06	1.22e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.11e-06	1.22e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—EGFR—dilated cardiomyopathy	2.1e-06	1.21e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.1e-06	1.21e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.09e-06	1.21e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—EGFR—dilated cardiomyopathy	2.07e-06	1.2e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—RAF1—dilated cardiomyopathy	2.07e-06	1.2e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.04e-06	1.18e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.03e-06	1.17e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—RAF1—dilated cardiomyopathy	2.03e-06	1.17e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—RAF1—dilated cardiomyopathy	2.02e-06	1.17e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—RAC1—dilated cardiomyopathy	2.02e-06	1.17e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—RAC1—dilated cardiomyopathy	2e-06	1.16e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—RAF1—dilated cardiomyopathy	1.98e-06	1.14e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—RAC1—dilated cardiomyopathy	1.97e-06	1.14e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—RAF1—dilated cardiomyopathy	1.97e-06	1.14e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—RAF1—dilated cardiomyopathy	1.96e-06	1.13e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—RAF1—dilated cardiomyopathy	1.95e-06	1.13e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—RAF1—dilated cardiomyopathy	1.94e-06	1.12e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AGT—dilated cardiomyopathy	1.93e-06	1.11e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—RAC1—dilated cardiomyopathy	1.93e-06	1.11e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—EGFR—dilated cardiomyopathy	1.92e-06	1.11e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—EGFR—dilated cardiomyopathy	1.92e-06	1.11e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—RAF1—dilated cardiomyopathy	1.91e-06	1.1e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—EGFR—dilated cardiomyopathy	1.91e-06	1.1e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.9e-06	1.1e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—RAC1—dilated cardiomyopathy	1.9e-06	1.1e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.89e-06	1.09e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AGT—dilated cardiomyopathy	1.88e-06	1.09e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—RAF1—dilated cardiomyopathy	1.87e-06	1.08e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—EGFR—dilated cardiomyopathy	1.85e-06	1.07e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AGT—dilated cardiomyopathy	1.84e-06	1.07e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.84e-06	1.06e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—EGFR—dilated cardiomyopathy	1.83e-06	1.06e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—TNF—dilated cardiomyopathy	1.82e-06	1.05e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—EGFR—dilated cardiomyopathy	1.82e-06	1.05e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.82e-06	1.05e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AGT—dilated cardiomyopathy	1.82e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AGT—dilated cardiomyopathy	1.81e-06	1.04e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.8e-06	1.04e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—RAF1—dilated cardiomyopathy	1.8e-06	1.04e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—RAF1—dilated cardiomyopathy	1.79e-06	1.03e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—EGFR—dilated cardiomyopathy	1.76e-06	1.02e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.75e-06	1.01e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—RAF1—dilated cardiomyopathy	1.74e-06	1.01e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—EGFR—dilated cardiomyopathy	1.73e-06	9.97e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.72e-06	9.91e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—EGFR—dilated cardiomyopathy	1.69e-06	9.77e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—RAF1—dilated cardiomyopathy	1.68e-06	9.72e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—RAC1—dilated cardiomyopathy	1.64e-06	9.48e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.63e-06	9.4e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—EGFR—dilated cardiomyopathy	1.63e-06	9.39e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—EGFR—dilated cardiomyopathy	1.62e-06	9.38e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—RAF1—dilated cardiomyopathy	1.62e-06	9.37e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RAC1—dilated cardiomyopathy	1.58e-06	9.14e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AGT—dilated cardiomyopathy	1.57e-06	9.06e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.56e-06	8.98e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—RAF1—dilated cardiomyopathy	1.55e-06	8.98e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.55e-06	8.95e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—RAF1—dilated cardiomyopathy	1.53e-06	8.85e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—EGFR—dilated cardiomyopathy	1.52e-06	8.78e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AGT—dilated cardiomyopathy	1.51e-06	8.73e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EGFR—dilated cardiomyopathy	1.5e-06	8.66e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—RAF1—dilated cardiomyopathy	1.5e-06	8.65e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.46e-06	8.4e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.44e-06	8.34e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—RAF1—dilated cardiomyopathy	1.44e-06	8.3e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EGFR—dilated cardiomyopathy	1.42e-06	8.21e-06	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.4e-06	8.1e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RAC1—dilated cardiomyopathy	1.4e-06	8.09e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.39e-06	8.03e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EGFR—dilated cardiomyopathy	1.39e-06	8.03e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EGFR—dilated cardiomyopathy	1.39e-06	8.01e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—EGFR—dilated cardiomyopathy	1.36e-06	7.84e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EGFR—dilated cardiomyopathy	1.35e-06	7.8e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EGFR—dilated cardiomyopathy	1.34e-06	7.74e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—RAF1—dilated cardiomyopathy	1.34e-06	7.74e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AGT—dilated cardiomyopathy	1.34e-06	7.73e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—EGFR—dilated cardiomyopathy	1.34e-06	7.72e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EGFR—dilated cardiomyopathy	1.33e-06	7.68e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—RAF1—dilated cardiomyopathy	1.33e-06	7.66e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EGFR—dilated cardiomyopathy	1.31e-06	7.58e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—RAF1—dilated cardiomyopathy	1.31e-06	7.55e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EGFR—dilated cardiomyopathy	1.28e-06	7.39e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—RAF1—dilated cardiomyopathy	1.28e-06	7.39e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—RAF1—dilated cardiomyopathy	1.26e-06	7.28e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.25e-06	7.24e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—dilated cardiomyopathy	1.23e-06	7.13e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—dilated cardiomyopathy	1.23e-06	7.09e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.19e-06	6.89e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.18e-06	6.8e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.12e-06	6.45e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—dilated cardiomyopathy	1.11e-06	6.43e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—RAF1—dilated cardiomyopathy	1.09e-06	6.29e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	1.08e-06	6.24e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CD36—dilated cardiomyopathy	1.05e-06	6.07e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—dilated cardiomyopathy	1.05e-06	6.07e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RAF1—dilated cardiomyopathy	1.05e-06	6.06e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—dilated cardiomyopathy	1.03e-06	5.93e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—dilated cardiomyopathy	9.85e-07	5.69e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AGT—dilated cardiomyopathy	9.47e-07	5.47e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RAF1—dilated cardiomyopathy	9.29e-07	5.36e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—dilated cardiomyopathy	9.19e-07	5.31e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—dilated cardiomyopathy	9.1e-07	5.25e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—dilated cardiomyopathy	8.97e-07	5.18e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—dilated cardiomyopathy	8.78e-07	5.07e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—dilated cardiomyopathy	8.64e-07	4.99e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—dilated cardiomyopathy	8.6e-07	4.96e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—dilated cardiomyopathy	7.2e-07	4.15e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	6.65e-07	3.84e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	6.48e-07	3.74e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—dilated cardiomyopathy	6.37e-07	3.68e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	5.83e-07	3.37e-06	CbGpPWpGaD
